Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
63
resultados
Última actualización
16/03/2025 [07:19:00]
Resultados 50 a 63 de 63
Resumen de: WO2025018933A1
The present embodiments relate to an immunoassay kit capable of measuring p-tau205 in a sample and to methods involving the use of such an immunoassay kit. The present embodiment also relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to p-tau205 and that can be used in such an immunoassay kit.
Resumen de: US2025027956A1
Current application relates to the field of neurodegenerative diseases. Specifically, the present invention relates to screening methods to identify therapeutic candidates for the prevention and/or treatment of Alzheimer's disease. More particularly, said candidates overcome endolysosomal dysfunction resulting from an accumulation of APP-carboxyterminal fragments.
Resumen de: US2025027085A1
The present disclosure provides, inter alia, methods for treating neurodegenerative disease including Alzheimer's disease. Methods for restoring retromer complex function in a subject, methods for determining the progression of a neurodegenerative disease in a subject, and in vivo methods for identifying a DNA-binding profile of a dimeric transcription factor complex such as the retromer complex are also provided. Further provided are methods for restoring amyloid precursor protein (APP) homeostasis in a subject in need thereof, methods for restoring tau metabolism in a subject in need thereof, compositions and methods for preventing CREB3L2-ATF4 heterodimerization in a subject using such compositions, and methods for rescuing AP42-induced neuronal cell death in a subject using such compositions.
Resumen de: US2025027140A1
Disclosed is a method that enables detection of whether or not a subject is affected by a neurodegenerative disease, which method is simpler and more effective than conventional methods. This method includes the steps of: (a) preparing an extracellular vesicle fraction from a body fluid sample of the subject; (b) counting the number of extracellular vesicles contained in the extracellular vesicle fraction obtained in Step (a), to obtain the number of the extracellular vesicles; (c) measuring the total amount of short-chain RNA contained in all extracellular vesicles counted in Step (b), to obtain the total amount of short-chain RNA per extracellular vesicle; and (d) judging the subject as being affected by the neurodegenerative disease in a case where the total amount of short-chain RNA per extracellular vesicle obtained in Step (c) is larger than a total amount of short-chain RNA per extracellular vesicle obtained from a body fluid sample of a healthy individual.
Resumen de: US2025025442A1
The present invention includes compositions and methods of treating CNS-related conditions, comprising: administering an effective amount of a compound that lowers the levels of one or more branched-chain amino acids (BCAAs) or metabolites thereof, or any pharmaceutically acceptable salt thereof, wherein the CNS-related conditions is selected from the group consisting of Alzheimer's disease and any related forms of dementia including vascular dementia, Lewy body dementia, frontotemporal dementia, Creutzfeldt-Jacob disease, Wernicke-Korsakoff disease, and Huntington's disease, Multiple sclerosis, Parkinson's disease, autism, Amyotrophic lateral sclerosis (ALS), Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and epilepsy.
Resumen de: WO2025019870A1
Disclosed are neuronal nitric oxide synthase (nNOS) inhibitors for use in methods for reducing AβO-induced tau phosphorylation, reducing AβO formation and accumulation on neurons, and modulating neuronal nitric oxide synthase (nNOS).
Resumen de: WO2025016932A1
The present invention is directed to the field of dementia, providing non-purified CSF and CSF- derived EVs markers for differential dementia diagnosis in patients with Alzheimer's, Parkinson's and Lewy body dementia. It not only provides the markers, but equally the method in using said markers for differential dementia diagnosis amongst the aforementioned patients.
Resumen de: WO2025019457A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.
Resumen de: EP4495599A1
The present invention relates to an in vitro method for the diagnosis of Alzheimer's disease, comprising the determination of an apolipoprotein E (ApoE)-based biomarker selected from the group consisting of: presence, amount, or concentration ApoE having a size of 34 kDa in an ApoE aggregate having a size of 100 kDa; ratio of ApoE dimers/monomers detected in a native electrophoresis assay; and presence of ApoE dimers detected in a native electrophoresis assay. The present invention also relates to a kit for diagnosing Alzheimer's disease comprising reagents for carrying out the method of the invention.
Resumen de: KR20250011594A
본 발명은 치매 진단을 위한 광섬유 기반의 플라즈모닉 바이오센서의 제작방법과 이로부터 제작된 바이오센서에 관한 것이다. 본 발명은 상기 바이오센서를 제작하기 위해 세 가지 전략을 수행하였다. 첫째로, 광섬유 표면에 고정되는 금속 나노입자의 밀도를 최적화하여 바이오센서의 감도를 최적화하였다. 둘째로, 금속 나노입자의 크기를 증가시키는 금속 덧씌움(Capping) 공정을 수행하여 금속 나노입자의 산란 효율을 증가시켰다. 셋째로, 광섬유 표면 중 금속 나노입자가 고정되지 않은 베어(Bare) 표면을 식각하여 배경 신호를 감소시켰다. 상기 세 가지 전략에 따라 바이오센서를 제작하였고, 알츠하이머의 생체 표지자인 아밀로이드 베타(Amyloid Beta)를 측정하였다. 본 발명에 따른 바이오센서는 종래보다 더 낮은 검출 한계, 더 빠른 진단 시간, 더 높은 정확성을 나타내었다.
Resumen de: US2025020671A1
A method for detecting risk biomarkers for chronic neurodegenerative disorder of central nervous system called Alzheimer's disease (AD) is provided. AD is the most common cause of dementia, and it is characterized by extracellular senile plaques formed by the accumulation of amyloid β (Aβ) proteins and aggregation of tau proteins into intracellular neurofibrillary tangles in central nervous system. The present invention aims at developing a novel PoC based multiple AD biomarkers detection assay and method, such as Aβ1-40/Aβ1-42, tau protein and BDNF using multi-colored highly luminescent, non-photo-bleaching quantum dots (QDs), which provides an affordable and accurate means for early diagnosis of MCI, AD or dementia at homes, hospitals or near the patient bedsides.
Resumen de: US2025020635A1
The present disclosure provides methods, assays, kits, and uses thereof for screening candidate therapeutics for their tendency to induce phagocytosis in a cell. In one aspect, the present disclosure provides a method of assaying a candidate compound for its tendency to induce phagocytosis in a cell, the method comprising: contacting the cells with the candidate compound; contacting the cells with a target ligand bound to a fluorescent phagocytosis vesicle reporter having a fluorophore emission wavelength; nuclear staining the cells with a DNA-specific fluorescent stain; and measuring the fluorescence amplitude of the fluorescent phagocytosis vesicle reporter. In another aspect, the present disclosure provides a cell-health assay for testing compounds for their potential for treating neurodegenerative disorders.
Nº publicación: EP4492033A1 15/01/2025
Solicitante:
VITO NV [BE]
UNIV ANTWERPEN [BE]
VITO NV,
Universiteit Antwerpen
Resumen de: EP4492033A1
The present invention is directed to the field of dementia, providing non-purified CSF and CSF-derived EVs markers for differential dementia diagnosis in patients with Alzheimer's, Parkinson's and Lewy body dementia. It not only provides the markers, but equally the method in using said markers for differential dementia diagnosis amongst the aforementioned patients.
BOPI
Sede Electrónica
